We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Emmaus

News List

Emmaus Life Sciences Announces Withdrawal of MAA to European Medicines Agency americanpharmaceuticalreview
September 23, 2019
Emmaus Life Sciences announced the withdrawal of its marketing authorization application (MAA) to the European Medicines Agency (EMA) for Xyndari™ (glutamine) for the treatment of sickle cell disease.
Emmaus Granted European Patent for L-glutamine to Treat Diverticulosis americanpharmaceuticalreview
September 04, 2019
Emmaus Life Sciences has announced the allowance of patent application number 12860587.0, directed to the treatment of diverticulosis, by the European Patent Office.
Emmaus Announces Initiation of its Diverticulosis Study americanpharmaceuticalreview
July 09, 2019
Emmaus Life Sciences announced the screening of the first patient for the company's Pilot/Phase 1 study on the treatment of diverticulosis with pharmaceutical-grade L-glutamine (PGLG).